Taro Pharmaceutical Industries (NYSE:TARO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report report published on Sunday. The brokerage issued a strong-buy rating on the stock.

Separately, HC Wainwright cut shares of Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 price objective for the company. in a report on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Down 0.1 %

TARO opened at $42.42 on Friday. Taro Pharmaceutical Industries has a 12-month low of $27.37 and a 12-month high of $45.76. The firm has a market capitalization of $1.59 billion, a P/E ratio of 34.77 and a beta of 0.60. The stock has a fifty day moving average of $42.18 and a 200-day moving average of $40.46.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new stake in Taro Pharmaceutical Industries in the third quarter valued at about $65,000. PenderFund Capital Management Ltd. acquired a new position in shares of Taro Pharmaceutical Industries during the 4th quarter worth about $92,000. Strs Ohio increased its stake in shares of Taro Pharmaceutical Industries by 58.8% in the 3rd quarter. Strs Ohio now owns 2,700 shares of the company’s stock valued at $101,000 after acquiring an additional 1,000 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Taro Pharmaceutical Industries in the 4th quarter valued at approximately $105,000. Finally, SG Americas Securities LLC bought a new position in Taro Pharmaceutical Industries during the 3rd quarter worth approximately $141,000. Institutional investors own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.